Primary Myelofibrosis: Clinical Trials

624 trials for Primary Myelofibrosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

309 completed, 95 terminated, 90 recruiting, 47 active not recruiting. 281 Phase 2, 199 Phase 1, 60 Not applicable, 58 Phase 3, 9 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2281Completed 149, Terminated 47, Recruiting 33, Active not recruiting 19, Unknown 12, Withdrawn 12, Not yet recruiting 8, Suspended 1
Phase 1199Completed 95, Recruiting 35, Terminated 30, Active not recruiting 17, Withdrawn 10, Unknown 9, Not yet recruiting 2, Suspended 1
Not applicable60Completed 29, Terminated 11, Recruiting 7, Not yet recruiting 5, Unknown 4, Withdrawn 4
Phase 358Completed 35, Terminated 8, Active not recruiting 7, Recruiting 5, Unknown 2, Not yet recruiting 1
Early Phase 19Completed 5, Recruiting 3, Withdrawn 1
Phase 44Active not recruiting 1, Completed 1, Not yet recruiting 1, Unknown 1

Follow Primary Myelofibrosis: new trials by email Literature Review of Primary Myelofibrosis trials Research Report on Primary Myelofibrosis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT
imetelstat - High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation
Phase 1Not yet recruitingUniversity of Wisconsin, Madison272027-02-012026-11-02
WELL-MPN: A Digital Lifestyle App for Patients With MPNs
WELL-MPN Digital App - Myeloproliferative Neoplasms (MPNs)
Not applicableNot yet recruitingBrigham and Women's Hospital752027-01-012026-09-29
Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms
Oral THU-decitabine - Myelofibrosis, MPN - Accelerated or Blast Phase
Phase 2Not yet recruitingJohn Mascarenhas202027-01-012026-10-14
Revumenib in Patients With Myelofibrosis
Revumenib, Ruxolitinib, FEDRATINIB - Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Phase 1 / Phase 2Not yet recruitingJohn Mascarenhas322026-12-012026-07-29
Study of LusPACercept in Participants With Myelofibrosis Associated Anemia and Thrombocytopenia
Luspatercept, Pacritinib - Myelofibrosis
Phase 2Not yet recruitingCase Comprehensive Cancer Center502026-12-012026-11-13
Jaktinib in Ruxolitinib-Treatment Failure Myelofibrosis: A Multicenter, Prospective, Real-World Observational Study
Jaktinib - Myeloproliferative Neoplasms/Myelofibrosis
Not yet recruitingAffiliated Hospital of Nantong University802026-11-102026-11-09
A Multicenter, Prospective, Observational Study of Jaktinib in Newly Diagnosed Myelofibrosis
Jaktinib - Myeloproliferative Neoplasms/Myelofibrosis
Not yet recruitingAffiliated Hospital of Nantong University802026-11-102026-11-09
Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts
Momelotinib, Ruxolitinib - Myelofibrosis, Myelofibrosis (MF)
Phase 4Not yet recruitingSWOG Cancer Research Network2682026-11-012026-09-17
Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis
bomedemstat - Myelofibrosis
Phase 2Not yet recruitingUnited Lincolnshire Hospitals NHS Trust402026-11-012026-02-20
Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis
Flonoltinib Maleate orally - Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera
Phase 2Not yet recruitingChengdu Zenitar Biomedical Technology Co., Ltd1052026-11-012026-10-16
Peri-Transplant Gecacitinib in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Peri-Transplant Gecacitinib - Myelofibrosis, Primary Myelofibrosis (PMF)
Not applicableNot yet recruitingFirst Affiliated Hospital of Zhejiang University462026-11-012026-10-29
Gecacitinib Plus Luspatercept in Patients With Myelofibrosis and Anemia
Gecacitinib, Luspatercept - Myelofibrosis
Phase 2Not yet recruitingPeking Union Medical College Hospital312026-11-012026-11-16
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
Pacritinib, Selinexor - Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Phase 2RecruitingJohn Mascarenhas262026-10-232026-10-27
An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell Transplantation
gecacitinib Hydrochloride Tablets - Myeloid Neoplasms With Myelofibrosis
Phase 1 / Phase 2RecruitingRuijin Hospital102026-10-152026-10-28
Special Stains in Assessment of Bone Marrow Fibrosis
Bone Marrow Fibrosis
Not yet recruitingAssiut University602026-09-262026-10-01
Peri-graft Cytokine Profile: Influence of Hematologic Disease and Donor Type
Blood sampling - Myelofibrosis, Acute Leukemia
Not yet recruitingAssistance Publique - Hôpitaux de Paris962026-09-152026-09-04
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Placebo, Elritercept - Myelofibrosis, Anemia
Phase 3RecruitingTakeda3242026-09-102026-11-06
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia
Phase 1RecruitingCity of Hope Medical Center462026-09-092026-10-23
A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
DMR-001, Ruxolitinib - Myeloproliferative Neoplasms (MPNs)
Phase 1RecruitingDamora Therapeutics2502026-09-012026-10-27
Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis
ropeginterferon alfa- 2b, Ruxolitinib - Myelofibrosis
Phase 1RecruitingUniversity of Utah152026-08-212026-10-19

Showing 20 of 624. Sign in to see all of them.

Narrower conditions

Myeloproliferative Disorders (281)  ·  Leukemia, Myeloid, Acute (223)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (207)  ·  Myelodysplastic Syndromes (200)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (198)  ·  Multiple Myeloma (181)  ·  Polycythemia Vera (181)  ·  Lymphoma, Non-Hodgkin (176)  ·  Leukemia, Myelomonocytic, Chronic (174)  ·  Thrombocythemia, Essential (170)  ·  Hodgkin Disease (169)  ·  Lymphoma, Follicular (158)  ·  Lymphoma, Mantle-Cell (156)  ·  Burkitt Lymphoma (151)

Broader conditions

Hemic and Lymphatic Diseases (624)  ·  Bone Marrow Diseases (611)  ·  Hematologic Diseases (607)  ·  Myeloproliferative Disorders (343)  ·  Neoplasms (342)  ·  Neoplasms by Histologic Type (300)  ·  Hemorrhagic Disorders (283)  ·  Pathological Conditions, Signs and Symptoms (280)  ·  Leukemia, Myeloid (275)  ·  Pathologic Processes (273)  ·  Disease Attributes (264)  ·  Neoplasms by Site (264)  ·  Chronic Disease (260)  ·  Immune System Diseases (247)  ·  Immunoproliferative Disorders (237)

Interventions

ruxolitinib (102)  ·  Cyclophosphamide (68)  ·  fludarabine phosphate (61)  ·  Tacrolimus (49)  ·  Peripheral Blood Stem Cell Transplantation (46)  ·  Busulfan (45)  ·  Mycophenolic Acid (40)  ·  Whole-Body Irradiation (36)  ·  fludarabine (30)  ·  Antilymphocyte Serum (29)  ·  Methotrexate (29)  ·  Cyclosporine (27)  ·  Melphalan (26)  ·  Filgrastim (21)  ·  11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (19)

Sponsors

Fred Hutchinson Cancer Center (32)  ·  M.D. Anderson Cancer Center (32)  ·  Novartis Pharmaceuticals (24)  ·  City of Hope Medical Center (23)  ·  Incyte Corporation (23)  ·  National Cancer Institute (NCI) (17)  ·  Case Comprehensive Cancer Center (12)  ·  John Mascarenhas (11)  ·  Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (10)  ·  Masonic Cancer Center, University of Minnesota (10)  ·  Mayo Clinic (10)  ·  AbbVie (8)  ·  Celgene (8)  ·  Northwestern University (8)  ·  OHSU Knight Cancer Institute (8)

Countries

United States (451)  ·  Italy (101)  ·  Germany (75)  ·  France (72)  ·  Canada (63)  ·  United Kingdom (61)  ·  Spain (59)  ·  Australia (55)  ·  Belgium (44)  ·  China (39)  ·  South Korea (36)  ·  Israel (35)  ·  Poland (35)  ·  Hungary (27)  ·  Japan (27)

Top investigators

John Mascarenhas, MD (12)  ·  Ronald Hoffman, MD (7)  ·  Ayalew Tefferi, MD (6)  ·  Ryotaro Nakamura, MD (5)  ·  Jorge Cortes, MD (4)  ·  Ruben A. Mesa, MD (4)  ·  Ryotaro Nakamura (4)  ·  Srdan Verstovsek, MD (4)  ·  Alessandro Rambaldi, MD (3)

Results publications

PMID 37042865, PMID 39516087, PMID 40535755, PMID 41958363, PMID 42316774, PMID 23911705, PMID 26069290, PMID 28962635, PMID 29217781, PMID 31527168, PMID 32499241, PMID 33275766, PMID 34551507, PMID 37517413, PMID 41758981, PMID 42452788, PMID 42842696, PMID 10204198, PMID 11468154, PMID 15459300, PMID 15466923, PMID 15570084, PMID 17397698, PMID 17562873, PMID 18451242, PMID 18698002, PMID 18997171, PMID 19270260, PMID 19451433, PMID 19706886, PMID 19720904, PMID 19812383, PMID 19841031, PMID 20008298, PMID 20124511, PMID 20424252, PMID 20651074, PMID 20709666, PMID 20709904, PMID 20843246, PMID 21719601, PMID 21742281, PMID 21874061, PMID 22081489, PMID 22157574, PMID 22259028, PMID 22375970, PMID 22375971, PMID 22480131, PMID 22547163

NIH funding

P30CA033572 (13), P01CA108671 (12), 2023 (9), P30CA015083 (8), P30CA068485 (7), 2017 (6), P30CA006973 (6), P30CA043703 (6), 2018 (5), P30CA015704 (5), 2014 (4), 2015 (4), P01CA015396 (4), P30CA016086 (4), P30CA016672 (4)